Rachel Vatnsdal

Stock Analyst at JP Morgan

(1.2)
# 1887
Out of 5,368 analysts
67
Total ratings
44.19%
Success rate
12.53%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
TXG 10x Genomics
Maintains: Neutral
12 9
10.43 -13.71% 4 May 9, 2025
TWST Twist Bioscience
Maintains: Underweight
40 33
33.55 -1.64% 2 May 6, 2025
RGEN Repligen
Maintains: Overweight
200 190
127.54 48.97% 6 Apr 29, 2025
RVTY Revvity
Maintains: Neutral
120 100
93.46 7% 4 Apr 29, 2025
NVST Envista Holdings
Maintains: Neutral
20 19
18.45 2.98% 4 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
380 390
342.12 14% 4 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
50 55
71.25 -22.81% 3 Feb 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
50 55
49.26 11.65% 1 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
165 160
117.06 36.68% 6 Nov 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
650 670
402.51 66.46% 8 Sep 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
88 80
70.21 13.94% 3 Aug 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
17 20
5.04 296.83% 3 Aug 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Aug 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
1300 1400
1155.16 21.2% 2 Aug 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
5 6
10.31 -41.8% 4 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Apr 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
60 90
38.3 134.99% 2 Feb 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
250 270
200.65 34.56% 4 Dec 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Nov 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
90 45
n/a n/a 1 May 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
n/a
n/a n/a 2 Nov 10, 2022